Virginia agrees not to fully enforce state law banning conversion therapy for LGBTQ+ minors
The Virginia Department of Health Professions, represented by the state's office of the attorney general, entered into a consent decree with the Founding Freedoms Law Center last month, saying officials will not discipline counselors who engage in talk conversion therapy.
Shaun Kenney, a spokesperson with the Virginia Attorney General's Office, said on Tuesday his office was satisfied with the consensus.
'This court action fixes a constitutional problem with the existing law by allowing talk therapy between willing counselors and willing patients, including those struggling with gender dysphoria,' Kenney said in a statement. 'Talk therapy with voluntary participants was punishable before this judgment was entered. This result—which merely permits talk therapy within the standards of care while preserving the remainder of the law—respects the religious liberty and free speech rights of both counselors and patients.'
A Henrico Circuit Court judge signed the consent decree in June. Two professional counselors represented by the law center sued the state's health department and counseling board last September, arguing that the law violated their right to religious freedom.
The term 'conversion therapy' refers to a scientifically discredited practice of using therapy in an attempt to convert LGBTQ people to heterosexuality.
The practice has been banned in 23 states and the District of Columbia, according to the Movement Advancement Project, an LGBTQ+ rights think tank.
The practice has been a matter of dispute in several states. A ruling is expected any day from the Wisconsin Supreme Court over whether a legislative committee's rejection of a state agency rule that would ban the practice of 'conversion therapy' for LGBTQ+ people was unconstitutional.
The U.S. Supreme Court decided in March to take up a case from Colorado to determine whether state and local governments can enforce laws banning conversion therapy for LGBTQ+ children.
According to the law center, the Virginia consent decree applies not only to the two counselors but to all counselors in Virginia.
'We are grateful to the Defendants in this case and to the Attorney General, who did the right thing by siding with the Constitution,' the law center said in a statement.
Democratic Senate Majority Leader Scott Surovell, who backed the 2020 bill, blasted the decree.
'This was a statute that was enacted to save lives,' he told reporters during a Zoom session on Tuesday. 'All the research, all the professional psychiatric organizations have condemned conversion therapy. They say it doesn't work, and they say it's counterproductive.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
11 minutes ago
- Medscape
GPP Linked to Greater Healthcare Burden
TOPLINE: A retrospective US claims study found that adults with generalized pustular psoriasis (GPP) had significantly higher healthcare visits and costs than patients with plaque psoriasis alone. METHODOLOGY: Researchers conducted a retrospective analysis of 633 adults with GPP between 2016 and 2019 in a US claims database, of whom 344 had comorbid plaque psoriasis and 289 had GPP alone. They also assessed an equal number of 633 matched patients with plaque psoriasis. Nearly 70% of the patients were women, 58.1% were aged 45-54 years, and 64.8% had commercial insurance. The median follow-up time ranged from 2.5 to 2.9 years. Study outcomes were healthcare utilization and costs. TAKEAWAY: Patients with GPP demonstrated significantly higher median total visits than those with psoriasis alone (3 or 4 vs 2; P < .001), as well as increased outpatient/office visits (3 vs 2; P < .001) and laboratory use (2 vs 1; P < .05). Only patients with GPP had inpatient visits (34 patients) and ICU visits (1 patient); 12 patients with GPP vs 1 patient with psoriasis had emergency room visits only. Median total healthcare costs were $189 for all patients with GPP, $174 for those with GPP only, and $205 for those with GPP and psoriasis compared with $103 for those with psoriasis only (P < .001). Median outpatient/office costs were also higher for all patients with GPP ($180), those with GPP only ($168), and those with both GPP and psoriasis ($198) compared with those with psoriasis ($100; P < .001). Emergency room costs ranged from $58 to $1490 for 12 patients with GPP compared with $160 for 1 patient with plaque psoriasis. IN PRACTICE: The greater costs for healthcare resource utilization 'and associated costs for GPP versus plaque psoriasis underscore the need for improved long-term management of GPP,' the study authors wrote. Studies should evaluate the impact of new treatments on utilization of healthcare resources related to GPP, they added, noting that patients with GPP 'traditionally receive medications intended for plaque psoriasis, which lack evidence of effectiveness for GPP.' SOURCE: The study was led by Mark Lebwohl, MD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, and was published online on July 24 in the Journal of the American Academy of Dermatology. LIMITATIONS: Possible miscoding in the claims database was a limitation, and the study period predated the FDA approval of spesolimab for treating GPP. DISCLOSURES: The study was funded by Boehringer Ingelheim. Lebwohl and two other authors disclosed receiving research funds, honoraria, and consulting fees from multiple pharmaceutical companies including AbbVie, Amgen, Arcutis, Avotres, and Boehringer Ingelheim. One author also reported receiving stock options from Connect Biopharma and Mindera Health and being editor in chief of the Journal of Psoriasis and Psoriatic Arthritis. Three authors are Boehringer Ingelheim employees. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
New York Times
40 minutes ago
- New York Times
Have a Question About Death? A New Project May Have Answers.
Times Insider explains who we are and what we do and delivers behind-the-scenes insights into how our journalism comes together. Late last year, Amelia Pisapia confronted something she'd long been wrestling with. 'I was still holding a lot of grief around Covid,' said Ms. Pisapia, who spent the first year and a half of the pandemic assisting with resources for New York Times readers, such as a Covid-19-related explainer. 'With the five-year anniversary of Covid coming up, I was looking for a place to put that grief.' Ms. Pisapia, an editor on The Times's Projects and Initiatives team, pitched a series to her team titled 'Death in the Modern Age.' It would focus on end-of-life issues and serve as a resource for readers who might be grappling with their own mortality or coping with the loss of someone close to them. The first article in the series was about A.I. 'griefbots,' written by Colin Dickey, a writer whose work deals with the occult in America. The cornerstone of the project is an F.A.Q. titled 'Let's Talk About Death,' compiled from several hundred submissions from Times readers who either asked questions related to death and dying or shared personal experiences. It covers a spate of topics, from how to pay for end-of-life care to whether there is evidence of an afterlife. The F.A.Q. remains open, encouraging readers to continue submitting questions. 'There's no topic more evergreen than death,' Ms. Pisapia said. She added: 'Given reader interest and that it touches everyone, and every desk, we're hoping to keep it going.' In an interview last month, she discussed her goals for the project and the reader questions that have resonated with her the most. This interview has been condensed and edited. Tell us more about how this project came together. At this moment in the United States, there are a lot of people rethinking what they want in end-of-life care — whether because of the pandemic, finances, newly approved medical aid in dying laws, being a member of the so-called sandwich generation and caring for dying parents while raising children, or simply just wanting something different than a traditional funeral or burial. Want all of The Times? Subscribe.
Entrepreneur
41 minutes ago
- Entrepreneur
Building a Healthier Future Through Technology and Inclusion
What began as a challenging experience soon sparked a lifelong mission to protect patients, empower clinicians, and eliminate preventable deaths. Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur Asia Pacific, an international franchise of Entrepreneur Media. On your mark, get set, go.. Joe Kiani, Masimo founder, Executive Chairman of Willow and serial entrepreneur, reminisced fondly of memories of he and his sister racing through their neighborhood streets of Shiraz. That was before his sister's surgery. "After that, she couldn't even run," said Kiani Watching his sister struggle to walk again after her procedure was the first of his many exposures to a healthcare system that failed the people it was meant to serve. That moment, according to Kiani, changed everything. What began as a challenging experience soon sparked a lifelong mission to protect patients, empower clinicians, and eliminate preventable deaths. Today, Kiani is the founder and Executive Chairman of Willow, a startup focused on empowering people to change the trajectory of their health and lives through preventative healthcare. He's also a fierce advocate for health equity, inclusion, and transparency in medicine. But behind his innovations is a deeply personal journey, a story rooted in grit, perseverance, and the pursuit of purpose over profit. From Shiraz to Silicon Valley Born in Shiraz, Iran, Kiani immigrated to the United States with his family at age nine. They arrived with limited English, few resources, and a fierce determination to build a better life. The cultural and linguistic barriers were significant, but Kiani adapted quickly, fueled by an insatiable curiosity and passion for people. He became obsessed with electronics and by high school, was designing gadgets and circuit boards. At just 15, he began studying electrical engineering at San Diego State University. By 22, he'd earned both bachelor's and master's degrees. As a young man trailblazing a path in a landscape that needed evolution, he knew he was called to help create better healthcare systems than those that had let down the people he loved most in the past. But where to start? The Pulse Oximeter That Changed Everything That question found its answer inside the halls of a hospital. He found himself working with pulse oximeters, devices that measure blood oxygen, and quickly noticed something troubling. They weren't accurate when patients moved or had low perfusion. This wasn't a minor issue, lives were at stake. Kiani knew there had to be a better way. In 1989, he founded Masimo from his garage with a vision: create patient-monitoring technology that worked in real-world conditions. After years of trial and error, he developed Signal Extraction Technology® (SET®) a breakthrough that dramatically improved the accuracy of pulse oximetry. "Every sleepless night taught me this: when your mission is urgent, setbacks become fuel," added Kiani. Today, Masimo devices are used in hospitals worldwide and have helped prevent countless deaths. Fighting for Transparency and Accountability Innovation, however, was only half the battle. Kiani quickly encountered resistance from entrenched interests in the medical device industry. He was outspoken about unethical practices, from hidden pricing to anti-competitive behavior, and he didn't hesitate to name names. "Healthcare injustice doesn't wear a villain's face, it hides in forms, denials, and board rooms and waiting rooms. We need to pull it into the light," he added. That conviction led him to found the Patient Safety Movement Foundation in 2012. Its bold goal: achieve zero preventable deaths in hospitals by uniting clinicians, tech companies, and policymakers. The foundation pushed hospitals to adopt actionable patient safety goals and urged companies to share data, an effort Kiani personally led by convincing dozens of manufacturers to open up their proprietary systems. "It's one thing to build products that monitor life. It's another to remember the lives behind every data point. That's the heart of it all," he said. An Immigrant Champion for Inclusion Kiani's commitment to justice extends beyond medicine. As an immigrant who faced his share of hurdles, he is a vocal advocate for diversity in corporate leadership. Under his guidance, he has built teams and policies to foster inclusion and transparency. Kiani believes that diversity is not just ethical, it's strategic. "When people from different backgrounds collaborate, you get better ideas. More empathy. More breakthroughs," he said. Like Minded Labs and the Future of Connection Beyond his contributions to the healthcare industry, Kiani is exploring new frontiers. His latest venture, as CEO of Like Minded Labs, is aimed at enhancing human connection in an increasingly digital world. While details remain under wraps, the mission is clear: use technology to enrich human interactions. Purpose Over Profit Through every chapter of his life, Kiani's North Star has remained the same: impact. "Some people see leadership as power. I see it as responsibility, to amplify good ideas, protect your team's courage, and walk the path of truth even when it's inconvenient," he said. Joe Kiani's journey, from immigrant youth to tech visionary, is not just about building devices. It's about building a better, fairer, safer world. And for him, the work is far from over.
